Clearpoint Neuro Inc

Clearpoint Neuro Inc(CLPT)股票分析

$15.550

-0.381 (-2.45%)收盤時

Loading chart…
High
16.080
Open
15.730
VWAP
15.69
Vol
467.84K
Mkt Cap
155.75M
Low
15.442
Amount
7.34M
EV/EBITDA, TTM
-10.03

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.

AI analysis of Clearpoint Neuro Inc (CLPT)

hold

ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.

估值指標

The current forward P/E ratio for Clearpoint Neuro Inc (CLPT) is 12.11, compared to its 5-year average forward P/E of -12.78.

Forward P/E

Strongly Overvalued
5Y Average P/E
-12.78
Current P/E
12.11
高估
-2.91
低估
-22.65

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-20.27
Current EV/EBITDA
-10.03
高估
-7.74
低估
-32.81

Forward P/S

Fair
5Y Average P/S
9.11
Current P/S
8.52
高估
13.20
低估
5.01

Alphio AI Price Scenarios for CLPT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLPT

$14.75

情境價格

B

Base

Base · 50%CLPT

$14.47

情境價格

B

Bear

Bear · 25%CLPT

$13.96

情境價格

事件時間軸

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

17:00:00

Company Adjusts 2026 Revenue Guidance to $48M - $52M

17:00:00

ClearPoint Neuro Q2 Revenue at $10.88M, Below Consensus

2026-06-17 (ET)

09:30:00

ClearPoint Neuro Shares Rise 32% to $17.66

資訊

CLPT FAQ — answered by Alphio AI

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始